DOCSLIB.ORG

The Use of Azelaic Acid 15% Gel, Topical Retinoids, and Photoprotection in the Management of Rosacea and Comorbid Dermatologic Disorders Sheri L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Use of Azelaic Acid 15% Gel, Topical Retinoids, and Photoprotection in the Management of Rosacea and Comorbid Dermatologic Disorders Sheri L CASE REPORT The Use of Azelaic Acid 15% Gel, Topical Retinoids, and Photoprotection in the Management of Rosacea and Comorbid Dermatologic Disorders Sheri L. Rolewski, MSN, CRNP, BC Rosacea is a common chronic, inflammatory disease of the skin that can significantly affect quality of life. Although the pathophysiology of rosacea remains unclear, most researchers and clinicians agree that it is a photoaggravated disorder and that the signs of rosacea often parallel those of photoaging and photodamage. The cases presented in this article underscore the relationship that may exist between UV light damage and rosacea. Fortunately, there is an array of topical medications that can help manage this photoaggravated disorder. Azelaic acid is a naturally occurring component of grains that has dem- onstratedCOS efficacy in the treatment of rosacea andDERM acne vulgaris. Although its mechanism of action is unknown, azelaic acid probably has anti-inflammatory and antioxidant effects. It also has been used suc- cessfully as monotherapy and in combination with tretinoin to treat dyschromias such as melasma and postinflammatory hyperpigmentation. The topical application of all-trans-retinoic acid has been shown to provide photoprotection and, with prolonged use, to repair UVA- and UVB-mediated skin damage. The Dounique combination of azelaicNot acid, topical tretinoin (offCopy label), and a physical sunblock can provide long-term management of rosacea. osacea is a common chronic, inflamma- we can empower our patients to gain control of their tory disease of the skin. Frequent facial disease (Table). flushing and sun damage, especially solar Although the pathophysiology of rosacea remains elastosis, are consistent characteristics of unclear, most researchers and clinicians agree that it is rosacea.1 Other signs include inflamma- a photoaggravated disorder.2,3 A study conducted by toryR lesions (papules and pustules). In addition, some Kosmadaki et al4 found that exposure to UV radiation patients develop phyma, or tissue overgrowth. This appears to trigger the release of vascular endothelial constellation of symptoms can significantly impact the growth factor, leading to new but distorted blood vessels quality of life of individuals with rosacea. Fortunately, that often become visible signs of rosacea (telangiecta- sias). Evidence suggests that prolonged exposure to UV Ms. Rolewski is Instructor of Dermatology and Family light can lead to a detrimental inflammatory process, Nurse Practitioner, Department of Dermatology, University of including the production of damaging oxygen free Pittsburgh, Pennsylvania. radicals.5-10 UV radiation stimulates angiogenesis (ie, tel- Ms. Rolewski is a member of the advisory board, serves as a angiectasias), vascular leakage, and a subsequent inflam- consultant, and is a member of the NP/PA Steering Committee matory cascade that alters the integument, contributing for Intendis. to signs and symptoms of rosacea.1,2,8-10 Signs of rosacea VOL. 20 NO. 4 • APRIL 2007 • Cosmetic Dermatology® 231 Copyright Cosmetic Dermatology 2010. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. MANAGEMENT OF ROSACEA with tretinoin in the treatment of dyschromias such as melasma and postinflammatory hyperpigmentation.20,21 Initial and Continuous Education The inflammatory lesions of perioral dermatitis have also for the Patient With Rosacea responded favorably to azelaic acid.22 Topical Retinoids Topical all-trans-retinoic acid has demonstrated photo- • Recognize that rosacea is a chronic, progressive, protective effects.23,24 The mechanisms responsible for inflammatory disease of the skin this photoprotection could involve anti-inflammatory • Identify and minimize triggers that induce flushing and antioxidant effects.25,26 These mechanisms, in addi- • Use a daily maintenance regimen to keep rosacea tion to the known ability of retinoids to normalize hyper- at bay keratinization, may be at least partially responsible for the efficacy of topical retinoids in dyschromias and inflam- • Listen to your skin and call your dermatologist if 27-29 you have any problems or concerns matory and keratotic dermatoses. Multiple studies, dating back to 1962, have proven tretinoin capable of • Follow up with an ophthalmologist to screen for or achieving complete regression of actinic keratoses (AKs) treat ocular rosacea and basal cell carcinomas.30-36 Its efficacy, however, is not • Request written educational material from your der- comparable to that of other treatment modalities, and it matologist as reinforcement is generally used adjunctively for this reason. It would be • Practice daily sun-smart behavior prudent, however, to use topical retinoids for chemopre- vention of precancerous lesions.37-41 • Use physical sunblock containing zinc oxide or tita- nium dioxide as daily moisturizer (sun protection The following cases illustrate the use of topical azelaic factor of 30 or above) acid and topical tretinoin for the treatment of various comorbid dermatologic conditions. • Reapply sunblock every 2 hours when exposed to UV radiationCOS DERM CASE REPORTS • Seek shade when feasible Case 1 • Wear protective clothing, eyewear, wide-brimmed hat This first case involved a 53-year-old woman who pre- sented with a 4-year duration of progressive facial red- ness that had become more pronounced in the previous often parallel those of photoaging and photodamage.3,11 2 years. The patient’s medical history was significant The Doclassic histopathologic signs Notof rosacea include dam- for basalCopy cell carcinoma, but negative for malignant age to the dermal matrix (elastosis) and damage to the melanoma or squamous cell carcinoma. She had an “itchy dermal collagen (collagenolysis).2,3,11 Indeed, according to spot” on the left cheek (mildly scaly, atrophic plaque) that Kligman,12 separating rosacea from advanced photodam- had been present for the previous 6 months. Also evident age is difficult, “because the two may come together.” were signs of solar lentigines, elastosis, and generalized Excessive sun damage may perhaps correspond to an dermatoheliosis. Additionally, she showed signs of mod- increased severity of rosacea, particularly the erythemato- erate, centralized, nonconfluent facial erythema, telangi- telangiectatic subtype. This correlation is seen within our ectasias, and multiple pink plaques (some with minimal large university-based practice. Unfortunately, there are scale) on her forehead (Figure 1A). The patient was diag- no large studies that associate the amount of photodam- nosed with AKs, dermatoheliosis, and moderate rosacea. age with severity of disease in patients with rosacea. Known triggers for her rosacea flares included alcohol, stress, weather and temperature changes, heat, and exer- TOPICAL THERAPEUTIC OPTIONS cise. At baseline she had not been treated previously for Azelaic Acid rosacea and did not use daily sunblock. Treatment Azelaic acid is a naturally occurring component of grains for the AKs included fluorouracil 0.5% cream once daily for that is available in a hydrogel formulation.13,14 It has an 6 weeks, applied sparingly to the cheeks and forehead. acceptable safety and efficacy profile and is generally well The patient was advised to discontinue therapy for 1 to tolerated in the treatment of rosacea.15-17 Its proposed anti- 2 days if the areas became tender, scabbed, or blister- inflammatory and antioxidant mechanisms also make it a like, to apply petroleum jelly or Aquaphor®, and then reasonable option for treating acne lesions.18,19 Addition- resume therapy when these adverse events resolved. She ally, various topical formulations of azelaic acid have been was also advised to engage in a monthly cutaneous self- used successfully as monotherapy and in combination examination and to present for an annual full cutaneous 232 Cosmetic Dermatology® • APRIL 2007 • VOL. 20 NO. 4 Copyright Cosmetic Dermatology 2010. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. MANAGEMENT OF ROSACEA Figure Not Figure Not Figure Not Available Online Available Online Available Online A B C Figure 1. A 53-year-old woman with actinic keratoses, dermatoheliosis, and moderate rosacea prior to topical therapy (A), 1 month after using azelaic acid 15% gel twice daily and tretinoin 0.05% cream every night (B), and 2 months after using azelaic acid 15% gel twice daily and treti- noin 0.05% cream every night (C). The actinic keratoses resolved, and dermatoheliosis and rosacea improved significantly. The actinic keratoses were treated with fluorouracil 0.5% cream daily for 6 weeks before topical therapy for rosacea was prescribed. examination with her dermatology health care provider. sulfacetamide 10% lotion for 4 years, tretinoin 0.05% Clinical findingsCOS following fluorouracil therapy resultedDERM cream for 6 years, and metronidazole 0.75% in both in resolution of the AKs. She was then prescribed azelaic gel and cream formulations for 6 years. She initially acid 15% gel twice daily and tretinoin 0.05% cream every presented with moderate, confluent facial erythema and night as maintenance therapy for rosacea. She was also telangiectasias that were greatest in the malar region. counseled about daily photoprotection and avoidance Enlarged pores were present without inflammatory pap- of rosacea triggers. The erythema and overall dermato- ules or pustules, and she did not complain of facial itch- heliosis
Load more

Recommended publications
  • Azelaic Acid
    Azelaic Acid (FINACEA) Topical Foam 15% National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Azelaic acid is a naturally occurring C9-dicarboxylic acid that is found in plants Action (such as whole grain cereals), animals and humans. Azelaic acid has antiinflammatory, antioxidative and antikeratinizing effects. In rosacea skin, azelaic acid decreases cathelicidin levels and kallikrein 5 (KLK5) activity and possibly inhibits toll-like receptor 2 (TLR2) expression.1 A 15% gel formulation has been marketed for rosacea, and 20% cream has been available for acne vulgaris. The newer foam formulation consists of an oil- in-water emulsion and was designed to have a higher lipid content than the gel for dry and sensitive skin. Indication(s) Under Review Topical treatment of inflammatory papules and pustules of mild to moderate in This Document rosacea. Dosage Form(s) Under Foam, 15% Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category B Executive Summary Efficacy There have been no head-to-head trials comparing the foam and gel formulations of azelaic acid in terms of safety, tolerability and efficacy in the treatment of papulopustular (PP) rosacea.. In two major randomized clinical trials, azelaic acid foam produced small benefits over vehicle foam in achieving Investigator’s Global Assessment (IGA) treatment success (NNTs of 9.2 and 11.5) and in reducing inflammatory lesion counts.
    [Show full text]
  • 2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
    2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL
    [Show full text]
  • CVS Formulary Drug Listing
    January 2021 Updated 11/01/2020 Performance Drug List - Standard Control The CVS Caremark® Performance Drug List - Standard Control is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • The member's prescription benefit plan design may alter coverage this document. Products recently approved by the U.S. Food and of certain products or vary copay1 amounts based on the condition Drug Administration (FDA) may not be covered upon release being treated.
    [Show full text]
  • Supply Issues Update for Primary and Secondary Care: September 2019
    COMMERCIAL-SENSITIVE Supply Issues Update for Primary and Secondary Care: September 2019 This report has been produced by the Department of Health and Social Care (DHSC) Medicine Supply Team. We aim to update this report monthly to provide an update on current primary and secondary care medicine supply issues that we are working on. This information is confidential to the NHS; please do not upload to websites in the public domain. Please do share with relevant colleagues and networks. Where it has been stated ‘a clinical memo from UKMI will be published on the SPS website’, this will be found at the following URL: https://www.sps.nhs.uk/category/shortages-discontinuations-and-expiries/ Acetylcholine Chloride (Miochol-E) 20mg Contents powder and solvent for irrigation ..................8 New Issues ............................................................. 3 Aciclovir 500mg/1g injection .........................8 Injectables ......................................................... 3 Amikacin 500mg/2ml injection ......................8 Diamorphine 5mg injection ........................... 3 Emerade 500 microgram and 300 microgram Adrenaline 1 in 1000, 1ml ampoules ............. 4 adrenaline auto-injector (AAI) devices ..........8 Lanoxin (digoxin) 250mcg/ml injection ......... 4 EpiPen and EpiPen Junior ..............................9 Sayana Press (medroxyprogesterone acetate Erwinase injection ..........................................9 104mg) injection ............................................ 5 Haloperidol 5mg/ml injection ........................9
    [Show full text]
  • Florida Medicaid Brand Drug Preferred List*
    FLORIDA MEDICAID BRAND DRUG PREFERRED LIST* Brand Name Generic Name Advair Diskus for inhalation fluticasone/salmeterol diskus Aggrenox capsules aspirin/dipyridamole Albenza tablets albendazole Androgel gel pack/pump** testosterone Avelox tablets** moxifloxacin Azactam vials aztreonam Benicar/Benicar-HCT tablets** olmesartan/olmesartan-HCTZ Bicnu vials carmustine Biltricide tablets praziquantel Butrans patch** buprenorphine transdermal Catapres TTS patch clonidine patch ER Cellcept suspension mycophenolate mofetil Cipro suspension (250mg/5ml & 500mg/5ml) ciprofloxacin Copaxone syringes 20mg glatiramer accetate/Glatopa Derma-Smoothe-FS oil fluocinolone 0.01% oil Differin cream and lotion adapalene erythromycin ethylsuccinate E.E.S. 200mg/5ml suspension - New addition suspension Elidel 1% cream pimecrolimus Emend capsules aprepitant Exelon patch rivastigmine transdermal Finacea GEL 15% azelaic acid Focalin XR capsules dexmethylphenidate hcl Gleevec tablets imatinib Mesylate Glyset tablets miglitol Humalog vial insulin lispro vial Kitabis Pak tobramycin pak Lamictal Dose Pak lamotrigine dose pak Lescol capsules / Lescol XL tablets** fluvastatin ER Letairis tablets** ambrisentan Lialda 1.2g tablets** mesalamine 1.2 g Lotemax 0.5% drops - New addition loteprednol 0.5% drops Makena single dose vial & auto inj** hydroxyprogesterone caproate vial Mephyton tablets phytonadione tablets Micardis and Micardis HCT tablets** telmisartan and telmisartan HCT Natroba suspension spinosad Norvir tablets ritonavir tablets Prevacid ODT lansoprazole ODT Proair
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Actinic Cheilitis
    ACTINIC CHEILITIS http://www.aocd.org Actinic cheilitis, also known as solar cheilosis, farmer’s lip, or sailor’s lip, is a reaction to long-term sun exposure on the lips, primarily the lower lip. The lip is especially susceptible to UV radiation because it has a thinner epithelium and less pigment. Some believe actinic cheilitis represents a type of actinic keratosis and is therefore premalignant. Others believe it is a form of in-situ squamous cell carcinoma. Regardless, the literature is in agreement that its presence indicates an increased risk for invasive squamous cell carcinoma. Risk factors for actinic cheilitis include fair complexion, everted lips, male sex, advanced age, living at high altitudes, living close to the equator, outdoor working, history of non-melanoma skin cancer, and any condition that increases photosensitivity. Clinically, patients commonly have other signs of sun damage such as poikiloderma of Civatte, solar lentigines, actinic keratoses, Favre-Racouchot Syndrome, cutis rhomboidalis nuchae, and solar elastosis. Patients often complain of persistent chapped lips or lip tightness. Early changes include atrophy and blurring of the vermilion border. The lips become scaly and rough; erosions or fissures may occasionally present. When palpated, it can have a sandpaper-like texture. Differential diagnosis can include chronic lip licking, granulomatous cheilitis, drug-induced cheilitis, contact dermatitis, cheilitis glandularis, lupus erythematosus, and lichen planus. An appropriate history can help elicit the proper diagnosis, such as inquiring about new medications or lip balms, lip-licking habits, and cumulative sun exposure. When actinic cheilitis is suspected, one must determine whether a biopsy is appropriate.
    [Show full text]
  • Treatment of Poikiloderma of Civatte with Ablative Fractional Laser Resurfacing: Prospective Study and Review of the Literature Emily P
    JUNE 2009 527 Vo l u m e 8 • Is s u e 6 CO P YR IGHT © 2009 ORIGINAL ARTICLES JOURN A L OF DRUGS IN DER MA TOLOGY Treatment of Poikiloderma of Civatte With Ablative Fractional Laser Resurfacing: Prospective Study and Review of the Literature emily P. Tierney MD and C. William Hanke MD MPH Laser and Skin Surgery Center of Indiana, Carmel, IN ABSTRACT Background: Previous laser treatments for Poikiloderma of Civatte (PC) (i.e., Pulsed dye, Intense Pulsed Light, KTP and Argon) are limited by side effect profiles and/or efficacy. Given the high degree of safety and efficacy of ablative fractional photothermolysis (AFP) for photoaging, we set out to assess the efficacy of PC with AFP. Design: A prospective pilot study for PC in 10 subjects with a series of 1−3 treatment sessions. Treatment sessions were adminis- tered at 6−8 week intervals with blinded physician photographic analysis of improvement at 2 months post-treatment. Evaluation was performed of five clinical indicators, erythema/telangiecatasia, dyschromia, skin texture, skin laxity and cosmetic outcome. Results: The number of treatments required for improvement of PC ranged from 1 to 3, with an average of 1.4. For erythema/te- langiecatasia, the mean score improved 65.0% (95% CI: 60.7%, 69.3%) dyschromia, 66.7% (95% CI: 61.8%, 71.6%), skin texture, 51.7% (95% CI: 48.3%, 55.1%) and skin laxity, 52.5% (95% CI: 49.6%, 55.4%). For cosmetic outcome, the mean score improved 66.7% (95% CI: 62.6%, 70.8%) at 2 months post treatment.
    [Show full text]
  • Preferred Drug List
    October 2021 Preferred Drug List The Preferred Drug List, administered by CVS Caremark® on behalf of Siemens, is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • This drug list represents a summary of prescription coverage. It is this document. Products recently approved by the U.S. Food and not all-inclusive and does not guarantee coverage.
    [Show full text]
  • Reticulate Dermatoses
    [Downloaded free from http://www.e-ijd.org on Tuesday, April 08, 2014, IP: 111.93.251.154] || Click here to download free Android application for this journal CME Article Reticulate Dermatoses Keshavmurthy A Adya, Arun C Inamadar, Aparna Palit From the Department of Dermatology, Venereology and Leprosy, SBMP Medical College, Hospital and Research Center, BLDE University, Bijapur, Karnataka, India Abstract The term “reticulate” is used for clinical description of skin lesions that are configured in a net-like pattern. Many primary and secondary dermatoses present in such patterns involving specific body sites. Certain cutaneous manifestations of systemic diseases or genodermatoses also present in such manner. This review classifies and describes such conditions with reticulate lesions and briefly, their associated features. Key Words: Mottling, net-like, reticulate, retiform What was known? 3. Poikilodermatous Reticulate configuration of lesions is seen in many primary dermatoses and a. Inherited also as cutaneous reaction patterns consequent to internal pathology. • Rothmund–Thomson syndrome • Dyskeratosis congenita Reticulate Dermatoses • Xeroderma pigmentosum • Cockayne syndrome The term “reticulate” is commonly used for clinical • Fanconi anemia description of “net-like”, “sieve-like,” or “chicken wire” • Mendes da Costa syndrome configuration of the skin lesions. Various congenital • Kindler syndrome and acquired dermatoses present with this pattern of • Degos–Touraine syndrome skin lesions. Many systemic diseases also present with • Hereditary sclerosing poikiloderma of Weary such cutaneous manifestations providing useful clues to • Hereditary acrokeratotic poikiloderma of Weary diagnosis. • Werner’s syndrome (adult progeria) Classification • Chanarin–Dorfman syndrome • Diffuse and macular atrophic dermatosis 1. Vascular b. Acquired a. Cutis marmorata • Poikiloderma of Civatte b.
    [Show full text]
  • Table I. Genodermatoses with Known Gene Defects 92 Pulkkinen
    92 Pulkkinen, Ringpfeil, and Uitto JAM ACAD DERMATOL JULY 2002 Table I. Genodermatoses with known gene defects Reference Disease Mutated gene* Affected protein/function No.† Epidermal fragility disorders DEB COL7A1 Type VII collagen 6 Junctional EB LAMA3, LAMB3, ␣3, ␤3, and ␥2 chains of laminin 5, 6 LAMC2, COL17A1 type XVII collagen EB with pyloric atresia ITGA6, ITGB4 ␣6␤4 Integrin 6 EB with muscular dystrophy PLEC1 Plectin 6 EB simplex KRT5, KRT14 Keratins 5 and 14 46 Ectodermal dysplasia with skin fragility PKP1 Plakophilin 1 47 Hailey-Hailey disease ATP2C1 ATP-dependent calcium transporter 13 Keratinization disorders Epidermolytic hyperkeratosis KRT1, KRT10 Keratins 1 and 10 46 Ichthyosis hystrix KRT1 Keratin 1 48 Epidermolytic PPK KRT9 Keratin 9 46 Nonepidermolytic PPK KRT1, KRT16 Keratins 1 and 16 46 Ichthyosis bullosa of Siemens KRT2e Keratin 2e 46 Pachyonychia congenita, types 1 and 2 KRT6a, KRT6b, KRT16, Keratins 6a, 6b, 16, and 17 46 KRT17 White sponge naevus KRT4, KRT13 Keratins 4 and 13 46 X-linked recessive ichthyosis STS Steroid sulfatase 49 Lamellar ichthyosis TGM1 Transglutaminase 1 50 Mutilating keratoderma with ichthyosis LOR Loricrin 10 Vohwinkel’s syndrome GJB2 Connexin 26 12 PPK with deafness GJB2 Connexin 26 12 Erythrokeratodermia variabilis GJB3, GJB4 Connexins 31 and 30.3 12 Darier disease ATP2A2 ATP-dependent calcium 14 transporter Striate PPK DSP, DSG1 Desmoplakin, desmoglein 1 51, 52 Conradi-Hu¨nermann-Happle syndrome EBP Delta 8-delta 7 sterol isomerase 53 (emopamil binding protein) Mal de Meleda ARS SLURP-1
    [Show full text]